Two additions to the therapeutic armory to treat HFrEF3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Brigham and Women's Hospital, Boston, MA, USA
Scott D. Solomon describes the two new pharmacologic therapies for use in patients with heart failure with reduced ejection fraction that have been approved by the FDA in the past year: the heart-rate reducing agent ivabradine and sacubitril/valsartan, a combination of an ARB and a neprilysin inhibitor.
Vascular Biology Working Group Meeting at ACC 2016, Chicago, IL, USA
Scott D. Solomon, MD - Professor of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA